JESSICA ADWELL: Open Payments
NPI 1043833726 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,742 in 89 payments from 14 companies in 2025. Trend: 2023 $2,104 · 2024 $1,731 · 2025 $1,742
Food & beverage: $1,632Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $282 |
| Vanda Pharmaceuticals Inc. | 9 | $240 |
| Neurocrine BioSciences, Inc. | 7 | $215 |
| Otsuka America Pharmaceutical, Inc. | 14 | $180 |
| ABBVIE INC. | 15 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $169 |
| Corium, LLC | 4 | $109 |
| Lundbeck LLC | 4 | $107 |
| Supernus Pharmaceuticals, Inc. | 4 | $81 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $54 |
Products named: REXULTI, FANAPT, INGREZZA, AUSTEDO XR, VRAYLAR, CAPLYTA, Azstarys, Qelbree.
Industry payments across AL — which companies pay providers there.
